In our preliminary studies on J82 bladder cancer, GHRH agonist MR-409 downregulated the expression of IGF1-R, inhibited the phosphorylation of IGF1-R and its downstream AKT and ERK pathways. Here, IGF1R is linked to urinary bladder carcinoma.